Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1661-1669

  Jiang, Ning ^a   Liu, Na ^a   Yang, Fan ^b   Zhou, Qiming ^a   Cui, Ruixue ^a   Jiang, Wei ^a   He, Qingmei ^a   Li, Wenfei ^a   Guo, Ying ^a   Zeng, Jing ^a   Yun, Jingping ^a   Chen, Xinchun ^b   Zhou, Boping ^b   Sun, Ying ^a   Wang, Huiyun ^a   Chen, Zhuo G ^c   Ma, Jun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Third People's Hospital   (China)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

KIT; Nasopharyngeal carcinoma; OncoCarta; Oncogene mutation

Indexed keywords

ABELSON KINASE; B RAF KINASE; CD135 ANTIGEN; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; JANUS KINASE 2; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN RET; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER CELL LINE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NASOPHARYNX CARCINOMA; ONCOGENE; ONCOGENE H RAS; ONCOGENE N RAS; PIK3CA GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; RECURRENCE FREE SURVIVAL; SMOKING; TUMOR GENE; CHINA; DNA SEQUENCE; GENETICS; MIDDLE AGED; MUTATION; NASOPHARYNX TUMOR; TUMOR CELL LINE;

ADULT; CELL LINE, TUMOR; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NASOPHARYNGEAL NEOPLASMS; ONCOGENES; SEQUENCE ANALYSIS, DNA;

EID: 84921448025     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3376     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Lee AW, Sze WM, Au JS, et al: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116, 2005. (Pubitemid 40340904)
3. Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23: 6730-6738, 2005. (Pubitemid 46190268)
4. Bensouda Y, Kaikani W, Ahbeddou N, et al: Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128: 79-85, 2011.
5. Caponigro F, Longo F, Ionna F and Perri F: Treatment approaches to nasopharyngeal carcinoma: a review. Anticancer Drugs 21: 471-477, 2010.
6. Ma BB and Chan AT: Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Expert Rev Anticancer Ther 6: 383-394, 2006. (Pubitemid 44192920)
7. Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med 10: 789-799, 2004. (Pubitemid 39070849)
8. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004. (Pubitemid 38637993)
9. Shaw AT, Yeap BY, Mino-Kenudson M, et al: Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27: 4247-4253, 2009.
10. Misale S, Yaeger R, Hobor S, et al: Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536, 2012.
11. Bardelli A and Janne PA: The road to resistance: EGFR mutation and cetuximab. Nat Med 18: 199-200, 2012.
12. Klein G: Nasopharyngeal carcinoma (NPC) is an enigmatic tumor. Semin Cancer Biol 12: 415-418, 2002.
13. Hui AB, Lo KW, Leung SF, et al: Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int J Cancer 82: 498-503, 1999. (Pubitemid 29343447)
14. Fan CS, Wong N, Leung SF, et al: Frequent c-myc and Int-2 overrepresentations in nasopharyngeal carcinoma. Hum Pathol 31: 169-178, 2000. (Pubitemid 30090645)
15. Hui AB, Lo KW, Teo PM, To KF and Huang DP: Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 20: 467-473, 2002.
16. Forbes SA BG, Bamford S, Dawson E, Kok C, Clements J, Menzies A, Teague JW, Futreal PA and Stratton MR: The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet: Chapter 10, 2008.
17. Chou CC, Chou MJ and Tzen CY: PIK3CA mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. Med Oncol 26: 322-326, 2009.
18. Yip WK, Leong VC, Abdullah MA, Yusoff S and Seow HF: Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 19: 319-328, 2008. (Pubitemid 351176090)
19. Fendri A, Khabir A, Mnejja W, et al: PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci 100: 2034-2039, 2009.
20. Naji F, Attaleb M, Laantri N, et al: Identification of G2607A mutation in EGFR gene with a significative rate in Moroccan patients with nasopharyngeal carcinoma. Cell Mol Biol 56: OL1442-OL1446, 2010.
21. Huang PY, Hong MH, Zhang X, Mai HQ, Luo DH and Zhang L: C-KIT overexpression and mutation in nasopharyngeal carcinoma cell lines and reactivity of Imatinib on these cell lines. Chin J Cancer 29: 131-135, 2010.
22. Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075, 2008.
23. Fumagalli D, Gavin PG, Taniyama Y, et al: A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer 10: 101, 2010.
24. Pao W and Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12: 175-180, 2011.
25. Liu N, Tang LL, Sun Y, et al: MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett 329: 181-188, 2013.
26. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al: Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 226: 84-96, 2012.
27. Duprez R, Wilkerson PM, Lacroix-Triki M, et al: Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol 226: 427-441, 2012.
28. Thomas RK, Baker AC, Debiasi RM, et al: High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351, 2007. (Pubitemid 46328493)
29. Pearce M, Hogg G, Hosseni D and Ehrich M: Mutation profiling in tumor samples using the Sequenom OncoCarta™ Panel. Nature Methods 6: vii-viii, 2009.
30. Jhawer M, Goel S, Wilson AJ, et al: PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961, 2008. (Pubitemid 351416582)
31. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncology 11: 521-529, 2010.
32. Tie J, Lipton L, Desai J, et al: KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17: 1122-1130, 2011.
33. Or YY, Hui AB, To KF, Lam CN and Lo KW: PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer 118: 1065-1067, 2006.
34. Qian CN, Guo X, Cao B, et al: Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res 62: 589-596, 2002. (Pubitemid 34106436)
35. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: D945-D950, 2011.
36. Su KY, Chen HY, Li KC, et al: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small- cell lung cancer. J Clin Oncol 30: 433-440, 2012.
37. Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102, 1999. (Pubitemid 29036292)
38. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
39. Kang S, Bader AG and Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 102: 802-807, 2005. (Pubitemid 40282746)
40. Abers GA, Ferris A, Craig M, et al: Mantle compensation of active metamorphic core complexes at Woodlark rift in Papua New Guinea. Nature 418: 862-865, 2002. (Pubitemid 34966302)
41. Qiu FH, Ray P, Brown K, et al: Primary structure of c-kit: relationship with the CSF-1/PDGF receptor kinase family - oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 7: 1003-1011, 1988.
42. Phung B, Sun J, Schepsky A, Steingrimsson E and Ronnstrand L: C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation. PLoS One 6: e24064, 2011.
43. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L and REMA: Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 138: 12-30, 2007.
44. Nakagomi N and Hirota S: Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 87: 365-371, 2007. (Pubitemid 46474567)
45. Longley BJ Jr., Metcalfe DD, Tharp M, et al: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 96: 1609-1614, 1999. (Pubitemid 29098499)
46. Growney JD, Clark JJ, Adelsperger J, et al: Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106: 721-724, 2005. (Pubitemid 40981272)
47. Lennartsson J and Rönnstrand L: Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 92: 1619-1649, 2012.
48. Ma BB, Lui VW, Poon FF, et al: Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. Invest New Drugs 28: 326-333, 2010.
49. Yasuda H, Kobayashi S and Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 13: e23-e31, 2012.
50. Rane SG, Cosenza SC, Mettus RV and Reddy EP: Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22: 644-656, 2002. (Pubitemid 34027508)
51. Vax VV, Bibi R, Diaz-Cano S, et al: Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours. J Endocrinol 178: 301-310, 2003. (Pubitemid 37063071)
52. Brose MS, Volpe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62: 6997-7000, 2002. (Pubitemid 35424092)
53. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002. (Pubitemid 34716871)
54. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005. (Pubitemid 40271173)
55. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004. (Pubitemid 38720929)